论文部分内容阅读
目的比较培美曲塞与吉西他滨治疗非小细胞肺癌晚期患者的临床疗效。方法回顾性总结我院收治的非小细胞肺癌晚期患者40例的临床资料。结果观察组经过治疗后痊愈者0例,显效者6例,稳定者10例,总有效率为30%,与对照组相比,两组数据具有一致性(P>0.05),而观察组不良反应发生率为5%,明显低于对照组不良反应发生率(20%)(P<0.05)。结论吉西他滨与培美曲塞方案对非小细胞肺癌晚期患者疗效类似,但培美曲塞疗法具有更低的不良反应发生率和更高的治疗安全性。
Objective To compare the clinical efficacy of pemetrexed and gemcitabine in the treatment of advanced non-small cell lung cancer patients. Methods The clinical data of 40 patients with advanced non-small cell lung cancer admitted to our hospital were retrospectively reviewed. Results In the observation group, 0 cases recovered, 6 cases markedly effective and 10 cases stable. The total effective rate was 30%. The data of the two groups were consistent (P> 0.05) The incidence of the reaction was 5%, which was significantly lower than that of the control group (20%) (P <0.05). Conclusion The gemcitabine and pemetrexed regimens have similar efficacy in advanced non-small cell lung cancer patients, but pemetrexed therapy has a lower incidence of adverse reactions and higher safety of treatment.